Amy Lynn Conners1, Katie N Jones1, Carrie B Hruska2, Jennifer R Geske3, Judy C Boughey4, Deborah J Rhodes5. 1. 1 Department of Radiology, Breast Imaging, Mayo Clinic, 200 First St SW, Rochester, MN 55905. 2. 2 Department of Radiology, Medical Physics, Mayo Clinic, Rochester, MN. 3. 3 Department of Biomedical Statistics, Mayo Clinic, Rochester, MN. 4. 4 Department of Surgery, Mayo Clinic, Rochester, MN. 5. 5 Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Abstract
OBJECTIVE: The purposes of this study were to compare the tumor appearance of invasive breast cancer on direct-conversion molecular breast imaging using a standardized lexicon and to determine how often direct-conversion molecular breast imaging identifies all known invasive tumor foci in the breast, and whether this differs for invasive ductal versus lobular histologic profiles. MATERIALS AND METHODS: Patients with prior invasive breast cancer and concurrent direct-conversion molecular breast imaging examinations were retrospectively reviewed. Blinded review of direct-conversion molecular breast imaging examinations was performed by one of two radiologists, according to a validated lexicon. Direct-conversion molecular breast imaging findings were matched with lesions described on the pathology report to exclude benign reasons for direct-conversion molecular breast imaging findings and to document direct-conversion molecular breast imaging-occult tumor foci. Associations between direct-conversion molecular breast imaging findings and tumor histologic profiles were examined using chi-square tests. RESULTS: In 286 patients, 390 invasive tumor foci were present in 294 breasts. A corresponding direct-conversion molecular breast imaging finding was present for 341 of 390 (87%) tumor foci described on the pathology report. Invasive ductal carcinoma (IDC) tumor foci were more likely to be a mass (40% IDC vs 15% invasive lobular carcinoma [ILC]; p < 0.001) and to have marked intensity than were ILC foci (63% IDC vs 32% ILC; p < 0.001). Direct-conversion molecular breast imaging correctly revealed all pathology-proven foci of invasive disease in 79.8% of cases and was more likely to do so for IDC than for ILC (86.1% vs 56.7%; p < 0.0001). Overall, direct-conversion molecular breast imaging showed all known invasive foci in 249 of 286 (87%) patients. CONCLUSION: Direct-conversion molecular breast imaging features of invasive cancer, including lesion type and intensity, differ by histologic subtype. Direct-conversion molecular breast imaging is less likely to show all foci of ILC compared with IDC.
OBJECTIVE: The purposes of this study were to compare the tumor appearance of invasive breast cancer on direct-conversion molecular breast imaging using a standardized lexicon and to determine how often direct-conversion molecular breast imaging identifies all known invasive tumor foci in the breast, and whether this differs for invasive ductal versus lobular histologic profiles. MATERIALS AND METHODS: Patients with prior invasive breast cancer and concurrent direct-conversion molecular breast imaging examinations were retrospectively reviewed. Blinded review of direct-conversion molecular breast imaging examinations was performed by one of two radiologists, according to a validated lexicon. Direct-conversion molecular breast imaging findings were matched with lesions described on the pathology report to exclude benign reasons for direct-conversion molecular breast imaging findings and to document direct-conversion molecular breast imaging-occult tumor foci. Associations between direct-conversion molecular breast imaging findings and tumor histologic profiles were examined using chi-square tests. RESULTS: In 286 patients, 390 invasive tumor foci were present in 294 breasts. A corresponding direct-conversion molecular breast imaging finding was present for 341 of 390 (87%) tumor foci described on the pathology report. Invasive ductal carcinoma (IDC) tumor foci were more likely to be a mass (40% IDC vs 15% invasive lobular carcinoma [ILC]; p < 0.001) and to have marked intensity than were ILC foci (63% IDC vs 32% ILC; p < 0.001). Direct-conversion molecular breast imaging correctly revealed all pathology-proven foci of invasive disease in 79.8% of cases and was more likely to do so for IDC than for ILC (86.1% vs 56.7%; p < 0.0001). Overall, direct-conversion molecular breast imaging showed all known invasive foci in 249 of 286 (87%) patients. CONCLUSION: Direct-conversion molecular breast imaging features of invasive cancer, including lesion type and intensity, differ by histologic subtype. Direct-conversion molecular breast imaging is less likely to show all foci of ILC compared with IDC.
Entities:
Keywords:
breast cancer; invasive ductal carcinoma; invasive lobular carcinoma; molecular breast imaging
Authors: Amy Lynn Conners; Carrie B Hruska; Cindy L Tortorelli; Robert W Maxwell; Deborah J Rhodes; Judy C Boughey; Wendie A Berg Journal: Eur J Nucl Med Mol Imaging Date: 2012-06 Impact factor: 9.236
Authors: M Boisserie-Lacroix; G Hurtevent-Labrot; S Ferron; N Lippa; H Bonnefoi; G Mac Grogan Journal: Diagn Interv Imaging Date: 2013-07-15 Impact factor: 4.026
Authors: Carrie B Hruska; Amy Lynn Conners; Katie N Jones; Amanda L Weinmann; Ravi K Lingineni; Rickey E Carter; Deborah J Rhodes; Michael K O'Connor Journal: EJNMMI Res Date: 2014-01-15 Impact factor: 3.138
Authors: Matthew F Covington; Ephraim E Parent; Elizabeth H Dibble; Gaiane M Rauch; Amy M Fowler Journal: J Nucl Med Date: 2021-12-09 Impact factor: 11.082
Authors: Michael K O'Connor; Melissa M B Morrow; Katie N Hunt; Judy C Boughey; Dietlind L Wahner-Roedler; Amy Lynn Conners; Deborah J Rhodes; Carrie B Hruska Journal: EJNMMI Res Date: 2017-01-14 Impact factor: 3.138